文献速递临床试验与 GCP

阿替普酶与阿司匹林对急性缺血性卒中轻微非致残性神经功能缺损患者功能结局的影响:PRISMS随机临床试验

Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2018-01-01

PRISMS试验纳入313例NIHSS 0-5分且非明确致残的急性缺血性卒中患者,随机接受阿替普酶或阿司匹林治疗。90天时阿替普酶组78.2%与阿司匹林组81.5%达到良好功能结局,校正风险差-1.1%(95%CI -9.4%至7.3%)。阿替普酶组症状性颅内出血发生率3.2% vs 0%。

要点

  • 对非致残性轻微卒中,阿替普酶未提高90天良好功能结局比例。
  • 阿替普酶组症状性颅内出血风险增加3.3%(95%CI 0.8%-7.4%)。
  • 试验提前终止,结论需谨慎解读。

核心结论

  • 在轻微非致残性急性缺血性卒中患者中,阿替普酶与阿司匹林相比未增加90天良好功能结局的可能性。
  • 研究提前终止,无法得出确定性结论,可能需要进一步研究。

研究设计与样本

  • PRISMS为3b期、双盲、双安慰剂、多中心随机临床试验,原计划纳入948例患者。
  • 实际纳入313例来自53个卒中网络的患者,平均年龄62岁(SD 13),女性144例(46%),中位NIHSS评分2分(IQR 1-3),中位治疗时间2.7小时(IQR 2.1-2.9)。

主要发现

  • 90天时,阿替普酶组122例(78.2%)与阿司匹林组128例(81.5%)达到良好功能结局(mRS 0或1)。
  • 校正风险差为-1.1%(95%CI -9.4%至7.3%)。
  • 阿替普酶组5例(3.2%)发生症状性颅内出血,阿司匹林组0例,风险差3.3%(95%CI 0.8%-7.4%)。

关键数值与推荐

  • 主要结局为90天改良Rankin量表评分0或1分。
  • 主要安全终点为静脉研究治疗后36小时内症状性颅内出血。
  • 阿替普酶标准剂量为0.9 mg/kg静脉给药,阿司匹林为口服325 mg。

临床怎么用

  • 对于NIHSS 0-5分且非明确致残的急性缺血性卒中患者,阿替普酶未显示功能结局获益且增加症状性颅内出血风险。
  • 临床决策需权衡出血风险与潜在获益,并考虑试验提前终止的局限性。

局限性

  • 试验提前终止,样本量远低于原计划,统计效能不足。
  • 研究结果不能推广至明确致残的轻微卒中患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: More than half of patients with acute ischemic stroke have minor neurologic deficits (National Institutes of Health Stroke Scale [NIHSS] score of 0-5) at presentation. Although prior major trials of alteplase included patients with low NIHSS scores, few without clearly disabling deficits were enrolled. OBJECTIVE: To evaluate the efficacy and safety of alteplase in patients with NIHSS scores of 0 to 5 whose deficits are not clearly disabling. DESIGN, SETTING, AND PARTICIPANTS: The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States. Patients with acute ischemic stroke whose deficits were scored as 0 to 5 on the NIHSS and judged not clearly disabling and in whom study treatment could be initiated within 3 hours of onset were eligible and enrolled from May 30, 2014, to December 20, 2016, with final follow-up on March 22, 2017. INTERVENTIONS: Participants were randomized to receive intravenous alteplase at the standard dose (0.9 mg/kg) with oral placebo (n = 156) or oral aspirin, 325 mg, with intravenous placebo (n = 157). MAIN OUTCOMES AND MEASURES: The primary outcome was the difference in favorable functional outcome, defined as a modified Rankin Scale score of 0 or 1 at 90 days via Cochran-Mantel-Haenszel test stratified by pretreatment NIHSS score, age, and time from onset to treatment. Because of early termination of the trial, prior to unblinding or interim analyses, the plan was revised to examine the risk difference of the primary outcome by a linear model adjusted for the same factors. The primary safety end point was symptomatic intracranial hemorrhage (sICH) within 36 hours of intravenous study treatment. RESULTS: Among 313 patients enrolled at 53 stroke networks (mean age, 62 [SD, 13] years; 144 [46%] women; median NIHSS score, 2 [interquartile range {IQR}, 1-3]; median time to treatment, 2.7 hours [IQR, 2.1-2.9]), 281 (89.8%) completed the trial. At 90 days, 122 patients (78.2%) in the alteplase group vs 128 (81.5%) in the aspirin group achieved a favorable outcome (adjusted risk difference, -1.1%; 95% CI, -9.4% to 7.3%). Five alteplase-treated patients (3.2%) vs 0 aspirin-treated patients had sICH (risk difference, 3.3%; 95% CI, 0.8%-7.4%). CONCLUSIONS AND RELEVANCE: Among patients with minor nondisabling acute ischemic stroke, treatment with alteplase vs aspirin did not increase the likelihood of favorable functional outcome at 90 days. However, the very early study termination precludes any definitive conclusions, and additional research may be warranted. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02072226.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Khatri P, Kleindorfer DO, Devlin T, et al. Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. JAMA. 2018. PMID: 29998337. doi:10.1001/jama.2018.8496

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。